Search Results
Your search for Javier Cortés, MD,Javier Cortés, MD matches 18 pages
Showing 1 - 18Pembrolizumab May Improve Breast Cancer Outcomes Regardless of Age or Menopausal Status
The addition of the immunotherapy drug pembrolizumab to chemotherapy prior to and following surgery may lead to improved outcomes in patients with breast cancer regardless of their age or menopausal status, according to new findings presented by Cardoso et al at the 2024 European Breast Cancer...
Two Studies Highlight Benefits in Quality of Life and Symptom Management With Novel Treatments of Advanced Breast Cancer
Recent improvements in overall and progression-free survival for patients with HER2-positive and estrogen receptor–positive breast cancers have not come at the expense of quality of life or symptom management, according to a pair of studies presented at the European Society for Medical Oncology...
PHERGain: Adapted-Response Trial Guides Treatment With Dual HER2 Blockade Alone
The phase II PHERGain trial, which employed a response-adapted strategy in the treatment of early-stage, HER2-positive breast cancer, has shown promising results for the selective use of HER2 blockade and de-escalation of chemotherapy.1 Nearly all patients assigned to skip chemotherapy prior to...
HER3-Targeting Antibody-Drug Conjugates Show Encouraging Results in Breast Cancer Subtypes
Early-phase data from the SOLTI TOT-HER3 and ICARUS-BREAST01 trials suggest that the novel HER3-directed antibody-drug conjugate patritumab deruxtecan may have beneficial activity in patients with hormone receptor–positive/HER2-negative and triple-negative breast cancer subtypes, according to...
T-DXd Improves Progression-Free Survival vs T-DM1 in Metastatic HER2-Positive Breast Cancer
As reported in The New England Journal of Medicine by Javier Cortés, MD, PhD, of the International Breast Cancer Center, Barcelona, and colleagues, the phase III DESTINY-Breast03 trial has shown significantly prolonged progression-free survival with fam-trastuzumab deruxtecan-nxki (T-DXd) vs...
Expert Point of View: Javier Cortés, MD, PhD
The invited discussant of the updated APHINITY data was Javier Cortés, MD, PhD, Head of the International Breast Cancer Center in Barcelona. “I think we clearly learned two things from the data. One is that estrogen receptor positivity does not matter in terms of benefit from the addition of...
KEYNOTE-355: Overall Survival With the Addition of Pembrolizumab to Chemotherapy in Advanced Triple-Negative Breast Cancer
As reported in The New England Journal of Medicine by Javier Cortés, MD, PhD, and colleagues, the phase III KEYNOTE-355 trial has shown improved overall survival with the addition of pembrolizumab to chemotherapy in previously untreated patients with advanced triple-negative breast cancer with a...
T-DXd Improves Progression-Free Survival vs T-DM1 in Metastatic HER2-Positive Breast Cancer
As reported in The New England Journal of Medicine by Javier Cortés, MD, PhD, of the International Breast Cancer Center, Barcelona, and colleagues, the phase III DESTINY-Breast03 trial has shown significantly prolonged progression-free survival with fam-trastuzumab deruxtecan-nxki (T-DXd) vs...
DESTINY-Breast03 Trial: T-DXd vs T-DM1 in Previously Treated Patients With Metastatic HER2-Positive Breast Cancer
As reported in The New England Journal of Medicine by Javier Cortés, MD, PhD, and colleagues, the phase III DESTINY-Breast03 trial has shown significantly prolonged progression-free survival with fam-trastuzumab deruxtecan-nxki (T-DXd) vs ado-trastuzumab emtansine (T-DM1) in patients with...
Identifying Women With Triple-Negative Breast Cancer Who May Benefit From Pembrolizumab Plus Chemotherapy
Results of the phase III randomized KEYNOTE-355 trial showed that the addition of the PD-1 inhibitor pembrolizumab to investigator’s choice of first-line chemotherapy improved progression-free and overall survival in women with metastatic triple-negative breast cancer compared with placebo and...
Identifying Women With Triple-Negative Breast Cancer Who May Benefit From Pembrolizumab Plus Chemotherapy
Results of the phase III randomized KEYNOTE-355 trial showed that the addition of the PD-1 inhibitor pembrolizumab to investigator’s choice of first-line chemotherapy improved progression-free and overall survival in women with metastatic triple-negative breast cancer compared with placebo and...
Javier Cortés, MD, PhD, on Previously Untreated Triple-Negative Breast Cancer: Pembrolizumab Plus Chemotherapy
Javier Cortés, MD, PhD, of the International Breast Cancer Center, discusses the final phase III results of KEYNOTE-355, which showed that pembrolizumab and chemotherapy improved overall and progression-free survival, compared with placebo and chemotherapy, for patients with previously untreated,...
DESTINY Breast03 Trial Supports Second-Line Use of T-DXd in Metastatic HER2-Positive Breast Cancer
The antibody-drug conjugate fam-trastuzumab deruxtecan-nxki (T-DXd) may become a new option as a second-line treatment of patients with HER2-positive unresectable or metastatic breast cancer, based on results from the global phase III DESTINY-Breast03 trial. These findings were presented by Javier...
Javier Cortés, MD, PhD, on HER2-Positive Breast Cancer: Trastuzumab Deruxtecan vs Trastuzumab Emtansine
Javier Cortés, MD, PhD, of Barcelona’s IOB Institute of Oncology, discusses phase III data from the DESTINY-Breast03 study, which support trastuzumab deruxtecan becoming the standard of care for second-line treatment of women with HER2-positive metastatic breast cancer (Abstract LBA1).
DESTINY Breast03: Second-Line Fam-Trastuzumab Deruxtecan-nxki for Metastatic HER2-Positive Breast Cancer
Fam-trastuzumab deruxtecan-nxki (T-DXd) showed statistically significant improvement in progression-free survival vs trastuzumab emtansine (T-DM1) in second-line treatment for HER2-positive unresectable or metastatic breast cancer, according to results from the global phase III DESTINY-Breast03...
Neoadjuvant Chemotherapy De-escalation Using F-18 FDG-PET Response–Based Strategy in HER2-Positive Breast Cancer
In the European phase II PHERGain study reported in The Lancet Oncology, Pérez-García et al found that an F-18 fluorodeoxyglucose positron-emission tomography (F-18 FDG-PET) response–based strategy may be able to identify patients with HER2-positive early breast cancer who may benefit from...
Unexpectedly Huge Survival Benefit With Pertuzumab and Trastuzumab in HER2-Positive Metastatic Breast Cancer
In my opinion, the combination of pertuzumab (Perjeta) and trastuzumab (Herceptin) is one of the most important advances in the field of metastatic breast cancer in the past 10 years. As recently reported by Swain, my other colleagues, and me and reviewed in this issue of The ASCO Post, the...
CLEOPATRA Overall Survival Analysis: Significant Benefit for Pertuzumab Plus Trastuzumab/Docetaxel in HER2-Positive Metastatic Breast Cancer
As reported in The New England Journal of Medicine by Sandra M. Swain, MD, of Washington Cancer Institute, MedStar Washington Hospital Center, and colleagues, the final prespecified overall survival analysis in the phase III CLEOPATRA study showed a significant 15.7-month increase in median overall ...
